Literature DB >> 8781328

Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy.

P Portincasa1, K J van Erpecum, P C van De Meeberg, G M Dallinga-Thie, T W de Bruin, G P van Berge-Henegouwen.   

Abstract

Extracorporeal shock-wave lithotripsy (ESWL) is an effective treatment in selected gallstone patients, but stone recurrence is a major drawback. Factors potentially influencing gallstone clearance and recurrence were studied in 84 patients in whom stone dissolution was diagnosed after ESWL plus bile salt therapy for initial solitary (n = 55) or multiple (n = 29) radiolucent stones. Apolipoprotein E (apoE) genotyping and gallbladder motility (sonography) were studied in a representative subgroup of patients (n = 50). The median follow-up after ESWL was 36 months (range, 4.5-67 months). Gallstone clearance was achieved after 8.7 months (range, 0.2-30 months). Independent factors significantly enhancing gallstone clearance were the presence of E4 allele; small initial gallstone size and number; effectiveness of fragmentation; and good gallbladder emptying (P = .002). Gallstone recurrence was seen in 30 patients after 18.6 months (range, 1.0-50 months). Cumulative gallstone recurrence rate (life-table analysis) was 15% within 1 year, increasing to 60% within 5.5 years. Although the probability of gallstone recurrence tended to be smaller in patients with initial solitary stones than in those with multiple stones during early follow-up, differences disappeared after long-term follow-up. Effective gallbladder emptying (residual volume < or = 6 mL) and apolipoprotein E4 (apoE4) independently influenced gallstone recurrence. Recurrence rate was higher (log rank test, P = .037) in those patients who were homozygous and heterozygous for the E4 allele compared with the individuals who were not expressing the apoE4 allele. Accordingly, there was an overrepresentation of the allele frequency for E4 in the group with gallstone recurrence (P =.03). Patients with small postprandial residual gallbladder volumes (</= 6 mL) had a lower probability of stone recurrence than those with large residual gallbladder volumes (log rank test, P = .0215). Biliary pain was more frequent with recurrence (55% vs. 13%, P = .001). The present study indicates that apoE4 genotype is associated with increased speed of gallstone clearance as well as a high risk of recurrence after ESWL. This finding points to a possible role for genetic factors in the pathogenesis of cholesterol gallstones. Effective gallbladder emptying is important for speed of clearance and prevention of recurrence. Patients with initial solitary stones have a decreased early- but not long-term gallstone recurrence rate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781328     DOI: 10.1002/hep.510240320

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Beneficial effect of sulphate-bicarbonate-calcium water on gallstone risk and weight control.

Authors:  Stefano Ginanni Corradini; Flaminia Ferri; Michela Mordenti; Luigi Iuliano; Maria Siciliano; Maria Antonella Burza; Bruno Sordi; Barbara Caciotti; Maria Pacini; Edoardo Poli; Adriano De Santis; Aldo Roda; Carolina Colliva; Patrizia Simoni; Adolfo Francesco Attili
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Effect of genetic variants related to lipid metabolism as risk factors for cholelithiasis after bariatric surgery in Brazilian population.

Authors:  Sidney Pinheiro-Júnior; Marcela A S Pinhel; Marcelo A Nakazone; Anielli Pinheiro; Gisele F S Amorim; Greiciane M S Florim; Camila M Mazeti; Michele L Gregório; Marina G Moschetta; Gilberto B Brito; Sérgio L A Brienze; Carla B Nonino; Antonio C Brandão; Dorotéia R S Souza
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

Review 3.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

Review 4.  An update on the pathogenesis of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Piero Portincasa
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

5.  The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects.

Authors:  M Niemi; K Kervinen; A Rantala; H Kauma; M Päivänsalo; M J Savolainen; M Lilja; Y A Kesäniemi
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

6.  Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China.

Authors:  Gabriella Andreotti; Jinbo Chen; Yu-Tang Gao; Asif Rashid; Bingshu E Chen; Philip Rosenberg; Lori C Sakoda; Jie Deng; Ming-Chang Shen; Bing-Sheng Wang; Tian-Quan Han; Bai-He Zhang; Meredith Yeager; Robert Welch; Stephen Chanock; Joseph F Fraumeni; Ann W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02-22       Impact factor: 4.254

7.  Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease.

Authors:  Zhao-Yan Jiang; Tian-Quan Han; Guang-Jun Suo; Dian-Xu Feng; Sheng Chen; Xing-Xing Cai; Zhi-Hong Jiang; Jun Shang; Yi Zhang; Yu Jiang; Sheng-Dao Zhang
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

8.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

9.  APOE and FABP2 Polymorphisms and History of Myocardial Infarction, Stroke, Diabetes, and Gallbladder Disease.

Authors:  Ikuko Kato; Susan Land; Jill Barnholtz-Sloan; Richard K Severson
Journal:  Cholesterol       Date:  2011-09-18

10.  Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.

Authors:  Fiona D M van Schaik; Raffaella M Gadaleta; Frank G Schaap; Saskia W C van Mil; Peter D Siersema; Bas Oldenburg; Karel J van Erpecum
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.